BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 17429445)

  • 1. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
    Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
    Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
    Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
    Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
    Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
    J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
    Kamiyama H; Zhou G; Roizman B
    Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
    Hoffmann D; Wildner O
    Cancer Gene Ther; 2007 Jul; 14(7):627-39. PubMed ID: 17479104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
    Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
    Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
    Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
    Griffith C; Noonan S; Lou E; Shillitoe EJ
    Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H; Saeki Y; Chiocca EA
    Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
    Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
    Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.